The global weight-loss drug market has quickly become one of the hottest battlegrounds in healthcare. The explosive popularity of obesity drugs like Wegovy, Ozempic, and Zepbound has created one of the fastest-growing pharmaceutical markets in the world, dominated by giants like Novo Nordisk (NVO) and Eli Lilly (LLY). But now one smaller biotech company — Viking Therapeutics (VKTX) — is drawing attention as a possible surprise challenger, thanks to promising clinical data for its obesity drug candidate VK2735 and plans for potential commercialization.
Let’s find out whether Viking stands a chance in this heated market.
